Preclinical News and Research

RSS

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

Researchers identifiy a promising strategy to reverse pulmonary fibrosis

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it.

30 Mar 2026

Noninvasive lung impedance monitoring improves outcomes in HFpEF patients

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with preserved ejection fraction (HFpEF), according to research presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Novo Nordisk principal scientist highlights the urgency of advancing human-relevant 3D tissue models ahead of the 11th 3D Tissue Models Summit

As regulatory momentum accelerates globally to reduce reliance on animal testing, leading experts in microphysiological systems (MPS), complex in vitro models (CIVMs), organoids, and organ‑on‑chip technologies are preparing to gather at the 11th 3D Tissue Models Summit, taking place April 28–30, 2026 in Boston.

From Hanson Wade Group - 11th 3D Tissue Models Summit 2026 27 Mar 2026

New initiative aims to scale individualized therapies for rare diseases

Critical Path Institute (C-Path) today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable development of advanced therapies for highly individualized conditions.

26 Mar 2026

Microfluidic chips enable realistic modeling of tumor immune environments

The challenge is that the tumor immune microenvironment is not a static backdrop but a constantly shifting ecosystem shaped by cancer cells, immune cells, stromal cells, cytokines, and physical barriers.

26 Mar 2026

Spear Bio introduces new ultra-sensitive neurodegenerative assays and expands direct access at AD/PD 2026

Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays—brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn)—at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026) last week.

From Spear Bio 26 Mar 2026

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

A narrative review in Food Science & Nutrition examined studies published from 2000 to 2025 and found that camel milk contains bioactive compounds with potential glycemic, anti-inflammatory, gut, and other health benefits. It also stressed that raw, unpasteurized camel milk poses microbial and zoonotic risks, underscoring that safety remains a key part of the story.

25 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

Passion fruit molecule may help prevent Alzheimer’s disease progression

Four years ago, a research group at the University of Oslo made what would turn out to be a major discovery.

25 Mar 2026

Can collagen supplements really improve your skin?

Investigating collagen peptides, this review explores their role in skin aging, assessing clinical evidence and the mechanisms behind their potential benefits.

25 Mar 2026

Systematic review identifies stress-induced biological triggers in oncology

Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses.

25 Mar 2026

Insilico and ASKA partner to advance AI-driven gynecological drug discovery

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology.

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

Internal compass helps the brain keep memories stable during change

A new discovery by McGill researchers sheds light on how we retain memories over time, even though brain activity is constantly changing.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

New compound targets the neuronal epigenome to treat Alzheimer's disease

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

19 Mar 2026

Cancer cells rely on glutathione as fuel for growth

Researchers discovered an antioxidant, glutathione, that cancer cells appear to be "addicted to" as fuel, opening new pathways for investigation and a potential drug that can restrict the way tumors use this nutrient.

18 Mar 2026